-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Is Expected To Breakeven In The Near Future
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Is Expected To Breakeven In The Near Future
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The US$2.6b market-cap company posted a loss in its most recent financial year of US$168m and a latest trailing-twelve-month loss of US$205m leading to an even wider gap between loss and breakeven. The most pressing concern for investors is ACADIA Pharmaceuticals' path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.
See our latest analysis for ACADIA Pharmaceuticals
Consensus from 20 of the American Biotechs analysts is that ACADIA Pharmaceuticals is on the verge of breakeven. They expect the company to post a final loss in 2023, before turning a profit of US$22m in 2024. The company is therefore projected to breakeven around 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 77%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.
NasdaqGS:ACAD Earnings Per Share Growth October 1st 2022Given this is a high-level overview, we won't go into details of ACADIA Pharmaceuticals' upcoming projects, however, bear in mind that by and large a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.
Before we wrap up, there's one aspect worth mentioning. ACADIA Pharmaceuticals currently has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which typically has high debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.
Next Steps:
This article is not intended to be a comprehensive analysis on ACADIA Pharmaceuticals, so if you are interested in understanding the company at a deeper level, take a look at ACADIA Pharmaceuticals' company page on Simply Wall St. We've also put together a list of relevant factors you should look at:
- Valuation: What is ACADIA Pharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether ACADIA Pharmaceuticals is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on ACADIA Pharmaceuticals's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
阿卡迪亚制药公司(纳斯达克代码:ACAD)可能会在业务上取得重大成就,所以我们想对该公司有所了解。Acadia制药公司是一家生物制药公司,专注于小分子药物的开发和商业化,以解决中枢神经系统疾病中未得到满足的医疗需求。这家市值26亿美元的公司在最近一个财年亏损1.68亿美元,最新一次往绩12个月亏损2.05亿美元,导致亏损与盈亏平衡之间的差距进一步扩大。投资者最迫切的担忧是阿卡迪亚制药公司的盈利之路--它什么时候能实现盈亏平衡?在这篇文章中,我们将触及对该公司增长的预期,以及分析师预计该公司何时能实现盈利。
查看我们对阿卡迪亚制药公司的最新分析
20位美国生物技术分析师的共识是,阿卡迪亚制药公司即将实现盈亏平衡。他们预计,该公司将在2023年公布最终亏损,然后在2024年实现2200万美元的盈利。因此,该公司预计在大约两年后实现盈亏平衡。为了在这一天实现盈亏平衡,公司必须以多大的速度实现同比增长?用一条最佳拟合线,我们计算出年均增长率为77%,这是非常令人振奋的。如果业务增长速度放缓,它将在比预期更晚的日期开始盈利。
纳斯达克:ACAD每股收益增长2022年10月1日鉴于这只是一个高层次的概述,我们不会深入讨论阿卡迪亚制药公司即将进行的项目的细节,但请记住,总的来说,生物技术公司的现金流不稳定,这取决于该公司所处的产品类型和开发阶段。这意味着高增长率并不罕见,尤其是如果公司目前处于投资期。
在我们结束之前,有一个方面值得一提。阿卡迪亚制药公司目前的资产负债表上没有债务,对于一家烧钱的生物技术公司来说,这是相当不寻常的,因为它的债务相对于股本通常很高。该公司目前完全依靠股东资金运营,没有债务义务,减少了对偿还的担忧,使其成为一项风险较低的投资。
接下来的步骤:
本文无意对阿卡迪亚制药公司进行全面分析,因此,如果你有兴趣更深入地了解该公司,不妨看看阿卡迪亚制药公司在Simply Wall St.上的公司页面。我们还整理了一系列相关因素,你应该看看:
- 估值:阿卡迪亚制药公司今天的价值是多少?未来的增长潜力已经计入价格因素了吗?我们免费研究报告中的内在价值信息图有助于直观地了解阿卡迪亚制药公司目前是否被市场错误定价。
- 管理团队:经验丰富的管理团队掌舵增加了我们对业务的信心-看看谁是阿卡迪亚制药公司董事会的成员和首席执行官的背景。
- 其他高表现股票:有没有其他股票可以提供更好的前景,并有经过证实的记录?在这里探索我们的这些伟大股票的免费列表。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧